Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-31

Study Completion Date

2022-01-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of \[C14\] CT1812

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers

NCT05248672

Alzheimer Disease

COMPLETED PHASE1

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790

Mild to Moderate Alzheimer's Disease

COMPLETED PHASE2

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

NCT03522129

Alzheimer Disease

COMPLETED PHASE1

Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

NCT02907567

Alzheimer's Disease

COMPLETED PHASE1/PHASE2

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

NCT05225415

Dementia With Lewy Bodies

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of \[C14\] CT1812 in 8 healthy male subjects

Subjects will be screened 28-days prior to dosing to determine eligibility.

Eligible subjects will be admitted to the clinical research unit (CRU) on Day -1. On Day 1, subjects will receive a single dose of CT1812 with a microtracer dose of \[14C\] CT1812. Whole blood, plasma, urine and fecal samples will be collection during the confinement period. Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.

Subjects will be and discharged from the CRU following completion of procedures 168 hours post dose (Day 8)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Open-label, single-dose study

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CT1812

Investigational Drug

Group Type EXPERIMENTAL

300 mg [C14] CT1812

Intervention Type DRUG

Single dose of 300 mg CT1812 with microtracer dose of \[C14\]

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

300 mg [C14] CT1812

Single dose of 300 mg CT1812 with microtracer dose of \[C14\]

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy, adult, male, 19 - 55 years of age
2. Male subjects must follow protocol specified contraception guidance as described in the protocol
3. Continuous non smoker who has not used tobacco/nicotine containing products for at least 3 months prior to dosing.
4. Body mass index (BMI) ≥18.0 and ≤30.0 kg/m2 at the Screening visit (subjects must not have experienced a weight loss or gain of \>10% within 4 weeks of dosing).
5. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI/designee at the Screening visit.
6. History of a minimum of 1 bowel movement per day.
7. Able to swallow multiple capsules.
8. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria

1. Evidence of disease that, in the opinion of the PI/designee, may influence the outcome of the study within 4 weeks before dosing
2. Clinically significant illness, in the opinion of the PI/designee, that requires medical treatment within 8 weeks prior to dosing, or a clinically significant infection that requires medical treatment within 4 weeks prior to dosing.
3. Any history of GI surgery that may affect PK profiles of CT1812
4. Has evidence of a clinically significant abnormality in physical examination findings, vital signs, or clinical laboratory determinations at the Screening visit or Check-in.
5. Has a clinically significant ECG abnormality at the Screening visit or Check-in.
6. Estimated creatinine clearance \<80 ml/min/1.73 m2 at the Screening visit.
7. Known history of clinically significant allergy to CT1812 or excipients at the Screening visit.
8. Has been diagnosed with acquired immune deficiency syndrome, or tests positive for human immunodeficiency virus (HIV), Hepatitis B virus surface antigen (HBsAg), or Hepatitis C virus (HCV) at the Screening visit.
9. Has a history of alcohol use disorder within the 2 years before the Screening visit.
10. Positive urine drug or alcohol results at the Screening visit or Check in.
11. Positive cotinine result at the Screening visit.
12. Unable to refrain from or anticipates the use of:

* Any drugs, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to dosing except for those allowed in the protocol
* Any drugs known to be significant inducers of CYP2D6 and CYP3A4 for 28 days prior to dosing.
13. Donation of blood or significant blood loss within 56 days prior to dosing.
14. Plasma donation within 7 days prior to dosing.
15. Poor peripheral venous access.
16. Recent history (within 2 weeks of Day 1) of abnormal bowel movements, such as diarrhea, loose stools, or constipation.
17. Has exposure to significant diagnostic or therapeutic radiation (e.g., serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to Check-in.
18. Has participated in a radiolabeled drug study where exposures are known to the PI within the previous 3 months prior to admission to the clinic for this study or participated in a radiolabeled drug study where exposures are not known to the PI within the previous 6 months prior to admission to the clinic for this study.
19. Has previously participated in a CT1812 investigational study.
20. Evidence or history of active suicidal thoughts in the 6 months preceding the screening visit; or have a history of a suicide attempt in the previous 2 years, or more than 1 lifetime suicide attempt; or are at serious suicide risk per the PIs clinical judgment.
21. Has any condition that would, in the opinion of the PI/designee or Sponsor, make the subject unsuitable for the study or is, in the opinion of the PI/designee, not likely to complete the study for any reason.
22. Participation in another clinical study within 30 days prior to dosing.

Minimum Eligible Age

19 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes